The paradigm for prostate cancer screening with PSA continues to evolve, as do complementary testing tools. Here’s one take from a longtime urologist.
Study suggests that novel prostate-specific antigen assay could significantly reduce unnecessary biopsies and help urologists provide men with the information needed to make informed decisions.
Commercialization of a medical product is a complex undertaking that requires expert oversight, rigorous assessment and perseverance. Here’s an insider’s perspective.
Cleveland Clinic urologists are playing leading roles in the development of next-generation prostate cancer biomarkers. One new test under investigation, prostate specific antigen/solvent interaction analysis (PSA/SIA), shows promise in improving the diagnostic accuracy of screening and early detection strategies by differentiating PSA structural changes induced by cancer from those of benign glands.